The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
TRAIL inhibits osteoclastic differentiation by counteracting RANKL‐dependent p27Kip1 accumulation in pre‐osteoclast precursors
Abstract
Experimental evidences indicate that the TNF family member TNF‐related apoptosis inducing ligand (TRAIL) might be involved in modulating osteoclastic differentiation. The ability of recombinant soluble TRAIL to affect bone density in vivo was evaluated by using 4‐week‐old mice subcutaneously (s.c.) injected with TRAIL for 8 days. TRAIL injection induced a significant increase of tibia trabecular thickness and total bone mass in 4‐week‐old mice, accompanied by a significant decrease of TRAP serum levels, without modulation of osteocalcin and osteoprotegerin (OPG). Parallel experiments performed in vitro showed that inhibition of osteoclastic differentiation, induced by treatment of human peripheral blood osteoclast precursors with TRAIL, was associated to inhibition of receptor activator of nuclear factor kappa B ligand (RANKL)‐induced accumulation of p27 Kip1. The potential role of p27 Kip1 pathway in mediating the anti‐osteoclastic activity of TRAIL was further suggested by in vitro gene knock‐down experiments performed in osteoclast precursor cultures. Taken together, our data strongly suggest that recombinant TRAIL inhibits osteoclastogenesis by inducing the ubiquitin‐mediated degradation of p27 Kip1. J. Cell. Physiol. 214:117–125, 2008. © 2007 Wiley‐Liss, Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33–35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [34]
In the citing paper
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33–35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [34]
Citations
Cites
Marching cubes: A high resolution 3D surface construction algorithm
Lorensen, W. E., & Cline, H. E. (1987) · ACM SIGGRAPH Conference (SIGGRAPH) · doi:10.1145/37401.37422 · Cited by 10,320
Marching cubes: A high resolution 3D surface construction algorithm
Lorensen, W. E., & Cline, H. E. (1987) · ACM SIGGRAPH Computer Graphics · doi:10.1145/37402.37422 · Cited by 8,928
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 3×
“Its cognate high affinity transmembrane receptor, receptor activator of nuclear factor kappa B (RANK) is expressed in both mature osteoclasts and their circulating precursor cells belonging to the monocytic/ macrophagic lineage (Boyle et al., 2003).”
BackgroundInfluentialOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc821 · Cited by 1,351
Tsvetkov, L. M., Yeh, K., Lee, S.-J., Sun, H., & Zhang, H. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80290-5 · Cited by 791
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Jono, S., Ikari, Y., Shioi, A., Mori, K., Miki, T., Hara, K., & Nishizawà, Y. (2002) · Circulation · doi:10.1161/01.cir.0000031524.49139.29 · Cited by 484
Bisphosphonate-Induced Osteopetrosis
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023110 · Cited by 441
Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease
Schoppet, M., Sattler, A., Schaefer, J. R., Herzum, M., Maisch, B., & Hofbauer, L. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020775 · Cited by 324
Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3839 · Cited by 318
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Holen, I., Croucher, P. I., Hamdy, F. C., & Eaton, C. L. (2002) · PubMed · Cited by 270
Shipman, C. M., & Croucher, P. I. (2003) · PubMed · Cited by 242
Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure
Ueland, T., Yndestad, A., Øie, E., Florholmen, G., Halvorsen, B. L., Frøland, S. S., Simonsen, S., Christensen, G., Gullestad, L. L., & Aukrust, P. (2005) · Circulation · doi:10.1161/01.cir.0000165119.62099.14 · Cited by 227
Vanderkerken, K., Leenheer, E. D., Shipman, C. M., Asosingh, K., Willems, A., Camp, B. V., & Croucher, P. I. (2003) · PubMed · Cited by 188
Prince, M., Banerjee, C., Javed, A., Green, J., Lian, J. B., Stein, G. S., Bodine, P. V. N., & Komm, B. S. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010301)80:3 · Cited by 182
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction
Ueland, T., Jemtland, R., Godang, K., KJEKSHUS, J. K., Hognestad, A., Omland, T., Squire, I. B., Gullestad, L. L., Bollerslev, J., Dickstein, K., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.076 · Cited by 181
Rasmussen, L. M., Tarnow, L., Hansen, T. K., Parving, H., & Flyvbjerg, A. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02049 · Cited by 148
Capparelli, C., Kostenuik, P. J., Morony, S., Starnes, C. O., Weimann, B., Van, G. Y., Scully, S. A., Qi, M., Lacey, D. L., & Dunstan, C. R. (2000) · PubMed · Cited by 147
Colucci, S. C., Brunetti, G., Rizzi, R., Zonno, A., Mori, G., Colaianni, G., Prete, D. D., Faccio, R., Liso, A., Capalbo, S. F., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0474 · Cited by 146
Neville-Webbe, H. L., Cross, N. A., Eaton, C. L., Nyambo, R., Evans, C. A., Coleman, R. E., & Holen, I. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000036900.48763.b3 · Cited by 141
Bisphosphonates: new therapeutic agents for the treatment of bone tumors
Heymann, D., Ory, B., Gouin, F., Green, J. R., & Rédiní, F. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.05.007 · Cited by 139
Zauli, G., Rimondi, E., Nicolin, V., Melloni, E., Celeghini, C., & Secchiero, P. (2004) · Blood · doi:10.1182/blood-2004-03-1196 · Cited by 115
Self-citationSevere hypocalcaemia after being given intravenous bisphosphonate
Peter, R., Mishra, V., & Fraser, W. D. (2004) · BMJ · doi:10.1136/bmj.328.7435.335 · Cited by 101
Pietro, R. D., Secchiero, P., Rana, R., Gibellini, D., Visani, G., Bemis, K., Zamai, L., Miscia, S., & Zauli, G. (2001) · Blood · doi:10.1182/blood.v97.9.2596 · Cited by 94
Self-citationCheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., & Murali, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309690200 · Cited by 92
Secchiero, P., Gonelli, A., Mirandola, P., Melloni, E., Zamai, L., Celeghini, C., Milani, D., & Zauli, G. (2002) · Blood · doi:10.1182/blood-2002-01-0047 · Cited by 84
Self-citationZauli, G., Vitale, M., Gibellini, D., & Capitani, S. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.1.99 · Cited by 68
Self-citationSecchiero, P., Gonelli, A., Celeghini, C., Mirandola, P., Guidotti, L., Visani, G., Capitani, S., & Zauli, G. (2001) · Blood · doi:10.1182/blood.v98.7.2220 · Cited by 67
Self-citationDeath receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis
Roux, S., Lambert-Comeau, P., Saint-Pierre, C., Lépine, M., Sawan, B., & Parent, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.092 · Cited by 67
Sankar, U., Patel, K., Rosol, T. J., & Ostrowski, M. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040321 · Cited by 54
A physical phantom for the calibration of three‐dimensional X‐ray microtomography examination
Perilli, E., Baruffaldi, F., Bisi, M. C., et al. (2006) · Journal of Microscopy · doi:10.1111/j.1365-2818.2006.01580.x · Cited by 41
Self-citationThai, L. M., Labrinidis, A., Hay, S. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4386 · Cited by 35
Heymann, D., Fortun, Y., Rédiní, F., & Padrines, M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03265-9 · Cited by 23
Cited by
Sorted by citations
Zaiss, M. M., Sarter, K., Hess, A., Engelke, K., Böhm, C., Nimmerjahn, F., Voll, R., Schett, G., & David, J. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27535 · Cited by 122
Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014716117 · Cited by 115
Metadata
- Authors
- Zauli, G., Rimondi, E., Stea, S., Baruffaldi, F., Stebel, M., Zerbinati, C., Corallini, F., & Secchiero, P.
- Affiliations
- University of Trieste (IT)
- University of Ferrara (IT)
- Istituto Ortopedico Rizzoli (IT)
- Corresponding author
- Zauli, Giorgio
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2007-07-09
- Volume
- 214
- Issue
- 1
- Pages
- 117-125
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2127114138
- Cited by
- 63
- References
- 35
- Citations by year
- 2026: 1 · 2023: 1 · 2020: 5 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 8 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 3
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cellular Physiology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- TRAIL, osteoclastogenesis, RANKL, p27, ubiquitin-mediated proteolysis, osteoclast precursors, bone mass, trabecular thickness, traps, osteoprotegerin, TNF family ligands
- MeSH terms
- Tartrate-Resistant Acid Phosphatase, Acid Phosphatase, Animals, Cathepsins, Cell Differentiation, Cell Nucleus, Cell Separation, Cells, Cultured, Drug Administration Schedule, Enzyme-Linked Immunosorbent Assay, Fluorescent Dyes, Humans, Indoles, Injections, Subcutaneous, Isoenzymes, Leukocytes, Mononuclear, Osteoclasts, Recombinant Proteins, Solubility, Osteocalcin, RNA, Small Interfering, Cyclin-Dependent Kinase Inhibitor p27, Mice, TNF-Related Apoptosis-Inducing Ligand, RANK Ligand, Cathepsin K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
